SAN FRANCISCO -- Scientists at the University of Pittsburgh Cancer Institute have begun to uncover how the virus that causes most Merkel cell carcinoma - a rare and aggressive skin cancer - operates, meaning that a rational chemotherapeutic target for this cancer could be developed in the near future.
Patrick Moore, M.D., M.P.H., an American Cancer Society professor in the laboratory of Yuan Chang and Patrick Moore at the University of Pittsburgh Cancer Institute in Pittsburgh, Pa., presented these study results at the Second AACR International Conference on Frontiers in Basic Cancer Research, held here Sept. 14-18, 2011.
Merkel cell carcinoma is a rare and highly aggressive cancer, the incidence of which has increased fourfold during the last 20 years, particularly in immunosuppressed populations, according to Moore.
"Unfortunately, Merkel cell carcinoma is difficult to treat and clinical trials of chemotherapeutics have been disappointing in affecting clinical course and survival," he said. "Discovery of the molecular cause for this cancer provides opportunities to directly target the cellular pathways that are perturbed by the virus."
In 2008, Moore and colleagues discovered Merkel cell polyomavirus (MCV), the virus that causes most Merkel cell carcinoma. Polyoma refers to the ability of some members of this family to produce multiple tumors in animal models. Their laboratory previously discovered the herpes virus that causes Kaposi's sarcoma, cancer that commonly occurs in patients with AIDS.
"MCV is the first polyomavirus to be consistently associated with human cancer, and is believed to cause 80 percent of Merkel cell carcinoma," Moore said.
MCV is a natural component of the human skin and is usually harmless, according to Moore. In fact, most adults carry the virus in some part of their skin cells. However, if someone becomes immunodeficient and the virus undergoes specific mutations, then it can generate Merkel cell carcinoma.
In the three years since they discovered MCV, this group has also discovered several of the unique characteristics of the virus. Most recently, their studies showed that MCV small T antigen protein is a new oncogene that can contribute to abnormal cell growth in both rodent and human cells. In addition, MCV does not act the same as other polyomaviruses that have served as classic models of cancer. These other polyomaviruses depend on viral interaction with the enzyme PP2A and heat-shock proteins; MCV interacts with them, but does not depend on them.
Moore and colleagues found that MCV could still cause the abnormal cell growth even after abolishing PP2A and heat-shock protein binding sites. The researchers hope to develop treatments that will directly target the cellular pathways affected by this virus.
"We are making headway on this approach now and have tested more than 1,350 drugs to identify better methods to treat this virus-caused cancer," Moore said.
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. AACR journals received 20 percent of the total number of citations given to oncology journals in 2010.